The power of the cooperative groups! - Stephanie Berg
Alliance for Clinical Trials in Oncology Toni Choueiri, MD Tian Zhang, MD, MHS Dan George Michael Morris Matt Galsky Jonathan Rosenberg MD
oncodaily.com/56060.html

#ClinicalTrials #Cancer #GenitourinaryOncology #OncoDaily #Oncology

A +ve CHMP opinion for gem/cis + nivolumab (CheckMate -901 trial) today Michiel van der Heijden Matt Galsky #APCCC24 Likely to result in EMA approval. This will compete with maintenance avelumab due to ⬆️ RR & CR rate, but EV/pembro will follow soon I hope . news.bms.com/news/corporate…

We are happy to share our new study published today Journal of Clinical Oncology (👉 ascopubs.org/doi/10.1200/JC…) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer.
With a huge contribution of our multinational team we uncovered…

Happy #ThankYouThursday to our incredible community of researchers, patients, and supporters! Your dedication to advancing cancer research through clinical trials is truly inspiring. Together, we are making a difference in the fight against cancer! #ClinicalTrials #Oncology #NCI

FIVE years while still staying relevant. Grit, more grit, and some more —-a journey like few others. Congrats to Alliance for Clinical Trials in Oncology investigators, Tian Zhang, MD, MHS as well as Dan George Michael Morris Matt Galsky Jonathan Rosenberg MD +stats team. Thank you to all the patients!

Tian: we…

Wow! Congrats to the A031704 team and all of the patients! 5 years in the making. The power of the cooperative groups! Tian Zhang, MD, MHS Toni Choueiri, MD Alliance for Clinical Trials in Oncology NCICancerTrials Atish Choudhury, MD PhD Alan Tan

Singapore Translational Cancer Consortium & Mount Sinai Hospital joining the IMCORE cancer research collaboration of 27 cancer centres & Roche. 96 cancer research project with >2000 scientists/HCPs and many high impact publications.Asian expansion reflects the global network

In my acceptance speech for the griffuel prize, I wore a silver dress to symbolize the “LIGHT” that science and advocates bring to humanity. I called on political leaders worldwide to be inspired by scientists’ commitment to a better and united world (1 out of 2)

Congratulations to our dear friend Rana for receiving the prestigious 2024 Christopher G. Wood Rising Star Award at the IKCS Europe, a well-earned recognition of her exceptional work in kidney cancer research! Your dedication and hard work have truly paid off. Cheers to your…

Congrats Miriam Merad, MD, PhD a 🌟! The Tisch Cancer Institute

1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

classic.clinicaltrials.gov/ct2/show/NCT05… MODERN is available to open through the CTSU

Trial in progress: the HER2/MMAE ADC disitimab Vedotin +pembro vs chemotherapy +\-avelumab in advanced UC(HER2+ve). DVs efficacy looks ⬆️ also with IO. Tox profile looks distinct with ? ⬇️ skin tox? #EAU24 Results will be considered in the context of other +ve 1st line studies

CTX130 is an investigational allogeneic, CRISPR/Cas9 gene-edited, anti-CD70 CAR T cell therapy with targeted disruption of the TRAC, β2M, and CD70 loci. We present in our paper preclinical activity of CTX130 across a variety of models - one snippet shown here: (2/5)

Thank you to Cancer Discovery for offering us the opportunity to publish our work, simultaneous with #AACR24 ! Grateful to Elizabeth McKenna for facilitating a thoughtful but rapid peer review process to get this out in time for the meeting.
In #kidneycancer , we have been fortunate to have…

Coinciding with #EAU24 & hopefully timely given terrific data from Matt Galsky from #CheckMate274 & Tom Powles from #IMvigor011 - our attempt at adjuvant tx w #FGFR3 inhibitor #infigratinib . Huge international effort w co-PI Sia Daneshmand, M.D. & terrific SC incl Shilpa Gupta…

Immune checkpoint blockade has become a standard adjuvant treatment strategy in patients with muscle-invasive urothelial cancer after surgery. Should we build on this strategy with personalized neoantigen vaccination? Tom Powles Uromigos Bladder Cancer Advocacy Network #AACR2024

Stephanie Berg Alliance for Clinical Trials in Oncology National Cancer Institute NCI Treatment Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Dana-Farber Lank Center for Genitourinary Oncology Another instance in which GU oncology is leading the way for every subspecialty in the field!

Elad Sharon Alliance for Clinical Trials in Oncology National Cancer Institute NCI Treatment Toni Choueiri, MD Sumanta K. Pal, MD, FASCO It’s almost open at the Dana-Farber Lank Center for Genitourinary Oncology and our regional campuses! Totally agree with you and de-escalation cohorts with potentially prognostic and predictive applications (A032103 is allowing crossover to Nivo if one converts to ctDNa+) is 💯 essential!

The inspiration for the Alliance for Clinical Trials in Oncology #MODERN study, and also so much more in the world of #ctDNA : classic.clinicaltrials.gov/ct2/show/NCT05… National Cancer Institute NCI Treatment Toni Choueiri, MD Sumanta K. Pal, MD, FASCO